Skip Navigation
Find a Doctor
 
 
 
 

 

Photo of Dr. Mark Schoenberg

Mark Schoenberg, MD

Director of Urologic Oncology
Professor of Urology

See Research on Pubmed

Male
Appointment Phone

410-955-6100

Main Location

Johns Hopkins Outpatient Center

View All Locations
Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-0773 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Titles

  • Director of Urologic Oncology
  • Bernard L. Schwartz Distinguished Professor of Urologic Oncology
  • Professor of Urology
  • Professor of Oncology

Centers & Institutes

  • Bladder Cancer Reseach Center
  • James Buchanan Brady Urological Institute
  • Sidney Kimmel Comprehensive Cancer Center

Expertise

Bladder Cancer, Lower Urinary Tract Reconstruction, Prostate Cancer, Urological Oncology, Urology, Urology / Urologic Surgery, Urology, Adult

Research Interests

Bladder cancer diagnostics and therapeutics; Bladder cancer; Lower urinary tract reconstruction; Prostate cancer; Urological oncology; Urology; Urologic surgery

Biography

Dr. Mark Schoenberg is a professor of urology and oncology at the Johns Hopkins School of Medicine. He is the Bernard L. Schwartz Distinguished Professor of Urologic Oncology and the director of the Division of Urologic Oncology. Dr. Schoenberg''s main academic focus and area of clinical activity is the treatment of patients with bladder cancer.

Dr. Schoenberg received his undergraduate degree from Yale. He earned his M.D. from the University of Texas School of Medicine. He completed his residency in urology at University of Pennsylvania Health System School of Medicine and performed a fellowship in urology at Johns Hopkins.

Dr. Schoenberg is involved in both basic and clinical research on the detection and management of patients with all forms of bladder cancer. His particular areas of clinical interest are the surgical treatment of invasive tumors and lower urinary tract reconstruction in both male and female patients.

Dr. Schoenberg is a member of the Society of Urologic Oncology, The American Urological Association and the American Association of Cancer Research. He is the author of the book The Guide to Living with Bladder Cancer.

Languages

  • English

Memberships

Society of Urologic Oncology, 1999-present

Fellow, American College of Surgeon, 1997-present

Maryland Urological Society/Medical and Chirurgical Faculty of Maryland, 1996-present

Bladder Health Council/A.F.U.D., 1996-2000

Mid-Atlantic Section, American Urological Association, 1995-present

American Urological Association, 1994-present

American Association of Cancer Research, 1994-present

Clinical Trial Keywords

  • Bladder Cancer Diagnostics and Therapeutics

Additional Resources

Additional Resources +
  • Education +

    Training

    • University of Texas Medical School at Houston ( Houston TX ) (1986)

    Residencies

    • University of Pennsylvania Health System School of Medicine/Urology ( Philadelphia PA ) (1992)

    Fellowships

    • Johns Hopkins University School of Medicine/Urology ( Baltimore MD ) (1994)

    Certifications

    • Urology, American Board of Urology (2005)
  • Research & Publications +

    Research Summary

    Dr. Schoenberg’s research group is focused on translational research in the area of urothelial malignancy. Their current work centers on evaluation of diagnostic technologies for bladder cancer as well as novel therapeutic agent evaluation within the context of approved clinical trials. The group has an extensive network of research interactions with investigators at peer institutions. A unique area of expertise within the research group is cancer monitoring in the occupationally exposed.

    The group has previously conducted large-scale monitoring of benzidine and o-toluidine exposed individuals. In addition, the group has experience working with individuals exposed to hormone disrupters (pesticides) and has previously monitored workers exposed to chlordimeform.

    The Bladder Cancer Research Center also manages the institutional bladder cancer database in collaboration with the Department of Pathology. The group is supported by funding through the Early Detection Research Network of the National Cancer Institute, project-specific funding from industry collaborators and philanthropy.

    Selected Publications View all on PubMed

    1. Kates M, Gorin MA, Deibert CM, Pierorazio PM, Schoenberg MP, McKiernan JM, Bivalacqua TJ. “In-hospital death and hospital-acquired complications among patients undergoing partial cystectomy for bladder cancer in the United States.” Urol Oncol. 2014 Jan;32(1):53.e9-53.e14. doi: 10.1016/j.urolonc.2013.08.024. Epub 2013 Nov 13.
    2. Tilki D, Shariat SF, Lotan Y, Rink M, Karakiewicz PI, Schoenberg MP, Lerner SP, Sonpavde G, Sagalowsky AI, Gupta A. “Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy.” BJU Int. 2013 Jun;111(8):1215-21. doi: 10.1111/j.1464-410X.2012.11455.x. Epub 2012 Nov 26.
    3. Hyndman ME, Kaye D, Field NC, Lawson KA, Smith ND, Steinberg GD, Schoenberg MP, Bivalacqua TJ. “The use of regenerative medicine in the management of invasive bladder cancer.” Adv Urol. 2012;2012:653652. Epub 2012 Aug 27.
    4. Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, Shipley WU, Heidenreich A, Schoenberg MP, Sagaloswky AI, Soloway MS, Stenzl A; International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012. “ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder.” Eur Urol. 2013 Jan;63(1):45-57. doi: 10.1016/j.eururo.2012.08.009. Epub 2012 Aug 14.
    5. Chaux A, Cohen JS, Schultz L, Albadine R, Jadallah S, Murphy KM, Sharma R, Schoenberg MP, Netto GJ.h. “High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues.” Hum Pathol. 2012 Oct;43(10):1590-5. doi: 10.1016/j.humpath.2011.11.016. Epub 2012 Mar 9.

    Clinical Trials

    A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)

  • Academic Affiliations & Courses +
  • Activities & Honors +

    Honors

    Pfizer Scholar, 1998

    Alpha Omega Alpha, University of Texas, 1986

    Professional Activities

    Chairperson, Scientific Advisory Board, the Bladder Cancer Advocacy Network, 2006-2008

    Nominating Committee, Mid-Atlantic Section/A.U.A., 2000-2001

  • Videos & Media +

    Videos

    Patient Steve Winick Talks About His Bladder Cancer Treatment at Johns Hopkins Medicine

    Four-time bladder cancer patient discusses his experience at Johns Hopkins, his radical cystectomy and his volunteer work as a mentor for other cancer patients.

    Video Links

    Recent News Articles & Media Coverage

    Raising Awareness about Bladder Cancer, The Diane Rehm Show, NPR

  • Upcoming Events +
  • Contact & Locations +

    Locations

    Johns Hopkins Outpatient Center
    601 N. Caroline Street
    Baltimore, MD 21287
    Phone: 410-955-1039
    Appointment Phone: 410-955-6100
    Fax: 410-955-0833
    Location Map
    The Johns Hopkins Hospital
    600 N. Wolfe Street
    Hospital Main Entrance - Sheikh Zayed Tower
    Baltimore, MD 21287
    Phone: 410-955-1039
    Appointment Phone: 410-955-6100
    Fax: 410-955-0833
    Location Map

    Department/Division

    • Urology

Is This You? Edit Profile

 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer